BofA Initiates Scholar Rock with Buy Rating: $53 Target on Promising SMA Therapy

Bank of America initiates coverage of Scholar Rock with Buy rating and $53 price target, citing apitegromab's breakthrough potential in spinal muscular atrophy treatment with $2B peak sales forecast.